Nyxoah's Genio: A Game Changer in Obstructive Sleep Apnea Treatment

Nyxoah, a medical technology company specializing in neuromodulation treatments for Obstructive Sleep Apnea (OSA), has announced the commercial launch of its innovative therapy, Genio, in England. This groundbreaking technology, now covered under the NHS Specialised Services Devices Programme (SSDP), is set to revolutionize the treatment landscape for OSA patients.

OSA, a condition characterized by repeated episodes of paused breathing during sleep, affects millions of people worldwide. Traditional treatments, such as Continuous Positive Airway Pressure (CPAP) machines, have limitations in terms of patient compliance and comfort. Nyxoah's Genio system offers a novel, minimally invasive solution that addresses these challenges.

The Genio system is a battery-free hypoglossal neuromodulation device inserted through a single incision under the chin and controlled by a wearable. It stimulates the hypoglossal nerve, which controls the tongue muscles, preventing airway collapse during sleep. Clinical studies have demonstrated best-in-class outcomes for reducing OSA burden, with high patient satisfaction and improved quality of life.

Nyxoah's successful completion of the BLAST OSA study led to the Genio system receiving its European CE Mark in 2019. Following positive outcomes from the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors' therapy. Additionally, the Company announced positive outcomes from the DREAM IDE pivotal study for FDA and U.S. commercialization approval.

The commercial launch of Genio in England marks an important milestone for Nyxoah, as it introduces its neurostimulation solution to treat OSA in the English market. The first successful implants were performed at University College London Hospitals (UCLH) by Mr. Ryan Chin Taw Cheong, Consultant ENT and Sleep Surgeon. Mr. Cheong expressed pride in being the first hospital in the UK to offer Genio to its OSA patients, highlighting the therapy's groundbreaking, clinically proven nature.

Olivier Taelman, CEO of Nyxoah, emphasized the significance of this achievement and the company's commitment to expanding its collaboration with UCLH and other leading hospitals in England. Nyxoah's mission to make sleep simple for OSA patients is poised to gain traction with the commercial launch of Genio in England.



The NHS Specialised Services Devices Programme (SSDP) coverage for Genio will significantly enhance its accessibility and adoption rates in England. By enabling access to innovative therapies through specialized centers of excellence, the SSDP will allow more patients to benefit from Genio's clinically proven, groundbreaking therapy for Obstructive Sleep Apnea (OSA). This coverage will not only expand Genio's reach but also validate its effectiveness, further boosting its reputation and demand. With the first successful implants already performed at University College London Hospitals (UCLH), Genio is poised to become a leading treatment option for OSA patients in England.

Nyxoah's commercial launch of Genio in England presents significant revenue streams and market share growth opportunities. The NHS Specialised Services Devices Programme (SSDP) coverage enables access to innovative therapies, with UCLH being the first hospital to offer Genio. With a market size of over 4 million OSA sufferers in the UK, and only 20% currently treated, there's substantial room for growth. Nyxoah's clinically proven, groundbreaking therapy addresses unmet needs, positioning it well to capture market share. Moreover, the company's commitment to innovation and clinical evidence, along with its successful IPOs and regulatory approvals, signals a strong trajectory for revenue growth in the English market.

In conclusion, Nyxoah's Genio system represents a significant advancement in the treatment of Obstructive Sleep Apnea. With its commercial launch in England, Genio is set to transform the lives of countless patients, offering a more comfortable and effective alternative to traditional treatments. As Nyxoah continues to expand its reach and collaborate with leading hospitals, the company is well-positioned to capture a substantial share of the English market and make a lasting impact on the global OSA treatment landscape.